ICICI Securities's research report on Torrent Pharma
Torrent Pharma’s (Torrent) Q1FY26 results were slightly below our expectations. Addition of MRs and price hikes continue to fuel growth in India (+10.8% YoY). Torrent has increased its field force by ~16% in the last one year and would further add another 400 in the next 2–3 quarters, taking the overall count to 7,000. It would also integrate 2,800 MRs of JB Chemicals post the acquisition of majority stake. Growth in Brazil and US bounced back in Q1; further, new launches too shall enable the momentum to sustain in these markets. Management expects FY26 margins to be at least ~33% levels. The acquisition of JB Chemicals is on track and Torrent is awaiting CCI’s response. We increase our FY26E/FY27E EBITDA by ~1% each to factor in better margins. Maintain HOLD with a higher TP of INR 3,530, based on 23x FY27E EV/EBITDA.
Outlook
We maintain HOLD with a higher target price of INR 3,530 (earlier INR 3,500), based on 23x FY27E EV/EBITDA (unchanged). We value the stock on EV/EBITDA(x) basis, considering a significant amortisation cost, which is a non-cash charge.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.